Number 1070 • November 2022

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS®

Temporary benefits added to the Alberta Drug Benefit List (ADBL)

Due to the unavailability of following amoxicillin oral suspension products, Auro-Amoxicillin 25 mg/ml Oral Suspension (DIN 02458586) and Auro-Amoxicillin 50 mg/ml Oral Suspension (DIN 02458594) manufactured by Auro Pharma will be considered temporary benefits for the *Alberta Drug Benefit List (ADBL)*. These groupings were added to the Critical Supply Product List on **November 4, 2022**.

Additionally, Ceftin 125 mg/5 ml Oral Suspension (DIN 02212307) manufactured by GlaxoSmithKline will also be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List on **November 7, 2022**.

DIN/NPN	Product Description
00000628131	Apo-Amoxi 25 mg/ml (Base) Oral Suspension
00000628158	Apo-Amoxi 50 mg/ml (Base) Oral Suspension
00002352753	Amoxicillin 50 mg/ml Oral Suspension
00002352788	Amoxicillin Sugar-Reduced 50 mg/ml Oral Suspension
00002401541	Amoxicillin 50 mg/ml Oral Suspension
00000452130	Novamoxin 50 mg/ml (Base) Oral Suspension
00001934163	Novamoxin Sugar-Reduced 50 mg/ml Oral Suspension

As of **November 4, 2022** and until further notice, all claims for Auro-Amoxicillin 25 mg/ml Oral Suspension (DIN 02458586) and Auro-Amoxicillin 50 mg/ml Oral Suspension (DIN 02458594) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)*.

As of **November 7, 2022** and until further notice, all claims for Ceftin 125 mg/5 ml Oral Suspension (DIN 02212307) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)*. The *ABCDPL* is available online at <u>ab.bluecross.ca/providers/pharmacy-home.php</u>.

Quarterly update regarding the Authorized Adjustment

The Alberta government, the Alberta Pharmacists' Association and Alberta Blue Cross continue working collaboratively to monitor pharmacy compensation expenditures and trends for drug benefit fees and pharmacy services. As previously communicated in Benefact 865, a provision exists to enable an Authorized Adjustment mechanism, through a consultative process, should expenditures trend towards exceeding established budget targets. With the completion of the second fiscal quarter (July 1 to September 30, 2022), expenditures remain within budget targets and, as a result, there was no need to initiate consultations on the Authorized Adjustment.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area) 403-294-4041 (Calgary and area) 1-800-361-9632 (toll free) FAX 780-498-8406 (Edmonton and area) FAX 1-877-305-9911 (toll free) Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php



